1 / 8

Elbasvir + Grazoprevir + Ribavirin in PI-experienced HCV GT1 C-SALVAGE

Phase 2. Treatment Experienced. Elbasvir + Grazoprevir + Ribavirin in PI-experienced HCV GT1 C-SALVAGE. (1) Buti M, et al. Clin Infect Dis. 2016;62:32-6. (2) Forns X, et al. J Hepatol . 2015;63:564-72.

niveditha
Download Presentation

Elbasvir + Grazoprevir + Ribavirin in PI-experienced HCV GT1 C-SALVAGE

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Phase 2 TreatmentExperienced Elbasvir + Grazoprevir + Ribavirin in PI-experienced HCV GT1C-SALVAGE (1) Buti M, et al. Clin Infect Dis. 2016;62:32-6. (2) Forns X, et al. J Hepatol. 2015;63:564-72.

  2. Elbasvir + Grazoprevir + Ribavirin in PI-experienced HCV GT1C-SALVAGE Study: Features Source: (1) Buti M, et al. Clin Infect Dis. 2016;62:32-6. (2) Forns X, et al. J Hepatol. 2015;63:564-72.

  3. Elbasvir + Grazoprevir + Ribavirin in PI-experienced HCV GT1C-SALVAGE Study: Design 0 12 24 Week PI+PR experienced Genotype 1 Non-cirrhotic (N=45)Cirrhotic (N=34) EBR + GZR + RBV N=79 SVR12 Abbreviations: EBR = elbasvir; GZR = grazoprevir; RBV = ribavirin; PI = protease inhibitor; PR = peginterferon+ribavirin Drug Dosing:Elbasvir: 50 mg once dailyGrazoprevir: 100 mg once dailyRibavirin (weight-based and divided bid): 800 to 1400 mg/day Source: Buti M, et al. Clin Infect Dis. 2016;62:32-6.

  4. Elbasvir + Grazoprevir + Ribavirin in PI-experienced HCV GT1C-SALVAGE Study: Participants Source: Forns X, et al. J Hepatol. 2015;63:564-72.

  5. Elbasvir + Grazoprevir+ Ribavirin in PI-experienced HCV GT1C-SALVAGE Study: Results C-SALVAGE: SVR 24* by Baseline Factors 76/79 63/66 33/36 32/34 * Analysis per protocol: excluding patients who dropped out due to reasons other than virologic failureRAVs = resistance-associated variants (at baseline) Source: Buti M, et al. Clin Infect Dis. 2016;62:32-6.

  6. Elbasvir + Grazoprevir + Ribavirin in PI-experienced HCV GT1C-SALVAGE Study: Results Source: Buti M, et al. Clin Infect Dis. 2016;62:32-6.

  7. Elbasvir + Grazoprevir+ Ribavirin in PI-experienced HCV GT1C-SALVAGE Study: Adverse Events Source: Forns X, et al. J Hepatol. 2015;63:564-72.

  8. Elbasvir + Grazoprevir+ Ribavirin in PI-experienced HCV GT1C-SALVAGE Study: Conclusions Source: Buti M, et al. Clin Infect Dis. 2016;62:32-6.

More Related